Login
PULSE BIOSCIENCES, INC. logo

PULSE BIOSCIENCES, INC.

pulsebiosciences.com

What Do They Do?

Sells and develops electrical-pulse ablation systems and disposable electrodes for cardiac surgeons, electrophysiologists, and soft-tissue clinicians.

How Do They Make Money?

Customers pay for the nPulse Vybrance system, components, software, and accessories, sold together or separately; payment generally comes shortly after delivery, according to the contract’s shipping terms.

FY2025 revenue

Who Are Their Customers?

U.S. sites evaluating the system and early commercial accounts use it under evaluation, consulting, or other early commercial agreements; customer contracts cover the system, software, and accessories.

Do Revenues Turn Into Profits?

No. It lost $72.8M in FY2025.

Operating income, FY2025
−21983% of revenue
▼ −37% (Loss) vs FY2024 (−$56.3M)
Net income, FY2025
−20795% of revenue
▼ −36% (Loss) vs FY2024 (−$53.6M)
Free cash flow, FY2025
−15553% of revenue
▼ −49% (Loss) vs FY2024 (−$36.5M)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +359%
vs $86K in Q3 FY2025
Net income
▼ −19% (Loss)
vs −$19.4M in Q3 FY2025

Shrinking. Revenue fell 75% in 4 years, from $1.4M in FY2021 to $350K in FY2025, about 30% a year.

Expanded into soft-tissue ablation The older report described development focused on cardiology and atrial fibrillation; the latest adds a percutaneous electrode for soft-tissue ablation and continued work in that area.

Who Do They Compete With?

Competes with Abbott Laboratories, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support